Work

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2069

Authors: Byoung Chul Cho, Myung-Ju Ahn, Jong-Seok Lee, Dong-Wan Kim, Sang-We Kim, Tom John, Stephen Chuan-Hao Kao, Jonathan Wade Goldman, Wu-Chou Su, Ronald B. Natale, Jin Seok Ahn, HyeRyun Kim, Tae Min Kim, Chia-Chi Lin, Philip Overend, Zhenfan Yang, James Chih-Hsin Yang

Institutions: Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, Seoul National University Bundang Hospital, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Olivia Newton-John Cancer Research Institute, Chris O’Brien Lifehouse, University of California, Los Angeles, National Cheng Kung University Hospital, National Cheng Kung University, Cedars-Sinai Medical Center, National Taiwan University Hospital, AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2673709515

Cites:

Cited by: 15

Related to: 10